EP
BBIO icon

Elkfork Partners’s BridgeBio Pharma BBIO Stock Holding History

Elkfork Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$225K Buy
10,494
+10,010
+2,068% +$277K 0.01% 797
2019
Q2 		$13K Buy
+484
New +$13.2K ﹤0.01% 1041

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Elkfork Partners's BBIO Position: Q3 2019 in Review

Elkfork Partners increased its BridgeBio Pharma (BBIO) stake by 2,068% in Q3 2019, buying an estimated $277K and bringing the position to 10,494 shares worth $225K. The position accounts for 0.01% of the portfolio, ranked #797.

Elkfork Partners first reported a position in BBIO in Q2 2019 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold BBIO as of Q3 2019.

  • Elkfork Partners held 10,494 shares of BridgeBio Pharma worth $225K as of Q3 2019.
  • Elkfork Partners bought 10,010 BridgeBio Pharma shares in Q3 2019, an estimated $277K.
  • BridgeBio Pharma made up 0.01% of Elkfork Partners's portfolio in Q3 2019, its #797 holding.
  • Elkfork Partners first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.